The Union ministry of health and family welfare (MoHFW) has prohibited the manufacture, sale and distribution of 16 fixed-dose combination (FDC) drugs across India, citing a lack of therapeutic justification and concerns that the potential risks associated with these formulations outweigh their clinical benefits.
According to the ministry, the decision is aimed at safeguarding public health, promoting the rational use of medicines and ensuring that only scientifically validated drug combinations remain available in the market.
Fixed-dose combination drugs contain two or more active pharmaceutical ingredients in a fixed ratio within a single dosage form. While many such combinations are widely accepted and medically justified, regulators have repeatedly expressed concerns about irrational formulations that provide little additional therapeutic benefit while potentially exposing patients to avoidable risks.
Supreme Court Mandated Review Led to Ban
The latest regulatory action follows directions issued by the Supreme Court for a comprehensive review of fixed-dose combinations marketed in India.
In compliance with the court's directions, the drugs technical advisory board (DTAB) constituted an expert committee to examine various FDC formulations available in the market.
The ministry said the committee conducted a scientific evaluation of the formulations and identified several combinations that were irrational, lacked therapeutic justification or posed potential risks to patients.
Based on the committee's recommendations, the government concluded that 16 FDC formulations did not offer sufficient therapeutic benefits relative to the risks associated with their continued use.
"The prohibited FDCs were found to lack therapeutic justification and their continued use was not considered beneficial in relation to the potential risks involved," the ministry said.
Antibiotic and Pain-relief Combinations among Those Banned
The prohibited formulations span multiple therapeutic categories, including antibiotics, analgesics, gastrointestinal medicines, anti-diabetic products and dermatological preparations.
Several of the banned products combine antibiotics with serratiopeptidase, an anti-inflammatory enzyme commonly used in India but whose therapeutic value in such combinations has frequently been questioned by medical experts.
The antibiotic-related combinations prohibited by the government include:
- Amoxicillin + Serratiopeptidase
- Amoxicillin + Serratiopeptidase + Lactobacillus Sporogenes
- Amoxicillin + Cloxacillin + Lactic Acid Bacillus + Serratiopeptidase
- Cefadroxyl + Probenecid
- Cefuroxime + Serratiopeptidase
The ban also covers certain pain-relief and gastrointestinal formulations, including:
- Dicyclomine + Paracetamol + Clidinium Bromide
- Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide
- Paracetamol + Lignocaine
- Acetyl Salicylic Acid + Ethoheptazine
In addition, several dermatological and cosmetic formulations containing combinations of aloe vera, vitamin E, jojoba oil, orange oil and other ingredients have been prohibited.
The anti-diabetic combination of Gliclazide and Chromium Picolinate has also been included in the list.
Continuing Crackdown on Irrational Drug Combinations
The latest action forms part of the government's ongoing efforts to eliminate irrational drug combinations from the pharmaceutical market.
Over the past decade, regulators have reviewed thousands of FDCs and prohibited several formulations found to lack adequate scientific evidence supporting their safety, efficacy or therapeutic value.
Health experts have consistently warned that irrational drug combinations can increase the risk of adverse reactions, complicate treatment protocols and, in the case of antibiotic formulations, contribute to antimicrobial resistance.
The ministry said the latest prohibition reinforces the government's commitment to evidence-based healthcare and patient safety.
"This action is in line with the Government's continuing efforts to ensure that only safe, effective and scientifically validated medicines are available to the public," it said.
Immediate Nationwide Enforcement
The ministry has directed state drug controllers and other regulatory authorities to ensure strict implementation of the prohibition orders.
Manufacturers, importers, distributors, wholesalers, retailers and other stakeholders have been advised to take immediate corrective steps to comply with the notifications.
With the ban now in force, the manufacture for sale, sale, distribution and supply of the identified 16 fixed-dose combinations for human use stand prohibited across the country.
The government said the move is intended to strengthen public confidence in India's drug regulatory framework and ensure that medicines available to patients are supported by sound scientific evidence and established therapeutic value.
List of 16 Fixed-dose Combination Drugs Prohibited by the Govt
- Acetyl Salicylic Acid + Ethoheptazine
- Aloe Extract + Allantoin + Alphatocopherol Acetate + D-Panthenol + Vitamin A
- Aloe Extract + Vitamin E + Dimethicone + Glycerine
- Aloe Vera + Jojoba Oil + Vitamin E
- Aloe Vera + Orange Oil
- Aloe Vera + Jojoba Oil + Wheat Germ Oil + Tea Tree Oil
- Aloe Vera + Vitamin E + Herbal Combination
- Dicyclomine + Paracetamol + Clidinium Bromide
- Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide
- Gliclazide + Chromium Picolinate
- Paracetamol + Lignocaine
- Amoxicillin + Serratiopeptidase + Lactobacillus Sporogenes
- Amoxicillin + Cloxacillin + Lactic Acid Bacillus + Serratiopeptidase
- Amoxicillin + Serratiopeptidase
- Cefadroxyl + Probenecid
- Cefuroxime + Serratiopeptidase
